[Influence on the prescription of antiepileptic drugs in Spain (2006-2017) after evaluations of committees or commissions].
The drug evaluation in a defined market becomes more important if we manage to objectify the impact of it on health care professionals. It has been collected all the information related to the autonomic committees of evaluation of drugs in a period of time (from April 2006 to May 2017) and in those who have produced reports related to the N3A therapeutic group (antiepileptics) and it has been measured the quantitative impact of their evaluations on the prescription habits of specialists in each of the autonomous communities and globally in Spain. The impact was measured by analyzing the sales data in units (IQVIA) by provinces and at national level of each product evaluated. The impact of the work carried out by the autonomous evaluation committees and by the therapeutic positioning reports in relation to the antiepileptic drugs has been practically non-existent or null. We consider from this forum the suitability or not to keep the investment of time, personnel and other resources in this type of approach.